Strasbourg IHU, First ex-aequo Laureate of the IHU call for proposals
Strasbourg's IHU project "Institute of Image-Guided Minimally Invasive Hybrid Surgery"
March 31, 2011
Build on a track record of revolutionizing surgeryStrasbourg played a significant role in the revolution from open to laparoscopic and robotic surgery, which led to measurable benefits in patient care and quality of life. IRCAD, founded at the University of Strasbourg Hospital by Prof. Jacques Marescaux, is recognized worldwide as a preeminent center for laparoscopic surgical research and training. Over 4,000 surgeons from 92 countries attend training courses in Strasbourg annually. The successful formula and increasing demand for training has driven the creation of international sites in Asia and Latin America. Moreover, IRCAD created WeBSurg.com, the top web-based surgical university with over 200,000 members. Finally, it produces innovative research in minimally invasive surgery with a track record of multidisciplinary teams transferring technology for the benefit of patients through public-private collaboration (19 Industry Partners). Leveraging IRCAD and the University of Strasbourg’s experience in guiding laparoscopic surgery will be a key advantage for the IHU in driving the future of MIX-Surg.
Construct a new infrastructure for patient care, research, innovation and technology transfer in the center of EuropeThe IHU will be ideally located in the center of Europe, facilitating Franco-German collaboration in medical device development. The IHU will be aligned with the University of Strasbourg, the top rated French University in Engineering and molecular biology, and with three main national Research Institutes (CNRS, INRIA and INSERM). The centerpiece of the IHU will be the unique platform of 17 hybrid operating rooms for patient care, education and research. These will be built in a single clinical, research and training complex designed to create a “cluster-effect” that optimizes creativity, problem solving and, ultimately, the transfer of technology.
Attract renowned physicians and industry leadersThe promise of developing new medical procedures and open new healthcare markets will allow to attract international thought leaders in medicine and engineering, and it will enable to partner with developing and established industry leaders. The IHU has provisional faculty commitments from the following thought leaders in medicine: L. Swanström (USA), T. Ponchon (FR), C. Ell (DE), P. Koninckx (B). Many companies share the IHU’s vision of creating hybrid operation based on minimally invasive surgery enabled by sophisticated imaging, computer assistance, robotics and advanced telecommunications. To date, 33 industry partners have committed to the IHU, including Siemens Healthcare (DE), Karl STORZ Endoskope (DE), Orange (FR), Thales (FR), ALTRAN (FR), Edap-TMS (FR)…
Expand an ambitious translational R&D program to drive ideas to realityThe IHU will bring together research and development labs with leaders in science, engineering and clinical practice whose work will directly impact MIX-Surg. The focus of research and development will be on patient-specific computer-assisted surgery, including medical imaging processing, biological modeling, targeted therapies, robotics, and hybrid medical device development. The IHU is dedicated to the clinical transfer of technology with the goal of bringing new ideas and procedures rapidly to the patient benefit of the healthcare system. This R&D initiative will inevitably attract a variety of entrepreneurial start-ups that will accelerate progress in the field of MIX-Surg. To facilitate technology transfer, the IHU will include a full time staff dedicated to Intellectual Property, technology licensing and business development so that promising projects will have the greatest chance of reaching patients.
Create a new training paradigm for healthcareThe evolution of surgery to incorporate image guidance, computer assistance, robotic augmentation and telecommunications will require a paradigm shift in the training of physicians, engineers, and other healthcare workers. The classic boundaries between medical, surgical and radiological disciplines must be reorganized to produce multidisciplinary teams who are proficient in all tools relevant to patients. The IHU will lead a broad effort to remodel training in healthcare and engineering to create the future leaders of MIX-Surg.
Enhance the primary National Grant with additional fundingThe IHU has major funding commitments in the first five years to finance the ambitious scope of the project. Commitments include €30 million from local authorities to build a dedicated IHU facility and over €80 million in funding and equipment from industry and private research partners. The IHU will additionally generate € 50 million independent revenue with the goal of a positive financial bottom line within ten years.
Invest in the local and National economyThe IHU is aligned with regional initiatives that identify medical technology as the most promising sector for local economic growth. The international market for minimally invasive hybrid procedures is estimated to grow at a mean annual rate of 8% to reach €37 billion in 2014. Unfortunately the market for minimally invasive technology does not have a single major French company despite the origin of many of these technologies in France. To fill this void, the IHU will partner with local authorities to develop a 5-hectar medical technology campus. The IHU Strasbourg could lead the creation of up to 2,000 new jobs, 10 industry R&D centers, and 40 small businesses over ten years, based on a joint assessment with McKinsey and Company. A Board of Trustees that includes political, investment and industry leaders will guide the business development of IHU initiatives.
Measure the economic impact and effect on public health of IHU activitiesThe IHU will form a dedicated impact analysis committee constituted by experts in health economics and business. This committee will analyze all IHU initiatives for both their impact on health outcomes and their commercial viability. The ultimate goal is to develop cost-effective procedures that succeed in the market by improving medical outcomes and patient's quality of life.
The investment in the IHU Strasbourg is expected to improve the practice of medicine, to serve as a platform for healthcare innovation and technology transfer, and to establish the presence of France in the international medical device industry.